Nada Elbuluk, MD, MSc, is a dermatologist in California. 

Susan Taylor, MD, a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. 

Where Are We in 2026 in Skin Health Equity Progress?

, Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale School of Medicine and host of 

, led a clinician-focused discussion with Susan Taylor, MD, the Bernett Johnson Endowed Professor of Dermatology at the University of Pennsylvania Perelman School of Medicine, and Nada Elbuluk, MD, MSc, board-certified dermatologist and Professor at the USC Keck School of Medicine, Department of Dermatology, on what “skin health equity” means in practice, and why this moment represents an inflection point for the 

Shahriari emphasized that the phrase “skin health equity” was chosen intentionally. For today’s dermatologists, she noted, the conversation must extend beyond isolated diagnoses or cosmetic concerns to encompass outcomes, access, education, and trust. What once was discussed quietly “in the hallways” is now visible in the literature, on social media, and across industry initiatives. The shift, she suggested, is from performative concern to measurable accountability: clinicians, institutions, and companies are increasingly being asked to demonstrate what they are doing differently.

Taylor reflected on why this period feels distinct from prior waves of discussion. In her view, one of the most tangible differences is therapeutic progress in diseases that have historically and disproportionately affected patients with skin of color. She pointed to hidradenitis suppurativa (HS) and atopic dermatitis as examples in which clinicians now have more effective and safer treatment options than in years past. These therapeutic advances, she explained, are complemented by educational gains, including expanded image collections and textbooks that more comprehensively depict dermatologic disease across a spectrum of skin tones. Such resources are critical for improving diagnostic accuracy and reducing delays in care.

Elbuluk agreed that the landscape has evolved from dialogue to accountability. She observed that journals, conferences, pharmaceutical companies, and even the cosmeceutical industry are now explicitly prioritizing health equity. Whereas prior limitations, such as a lack of diverse representation in research or educational materials, might have been passively accepted, there is now an expectation that organizations address these gaps. According to Elbuluk, that expectation signals a readiness within the field to pivot from aspiration to implementation.

Shahriari also framed equity as a patient safety issue. As the US population becomes increasingly diverse, she argued, the inability to effectively diagnose and manage dermatologic disease across heterogeneous skin types risks compromising care. For practicing clinicians, this reframing underscores that equity is not ancillary to core dermatologic practice; it is foundational to delivering safe, high-quality care.

The discussion also addressed ongoing gaps. Taylor highlighted clinical trials as an area of both progress and unfinished work. She cited efforts to increase the diversity of both investigators and study participants, noting initiatives supported by professional organizations and pharmaceutical companies. Trials intentionally designed to evaluate therapies in patients with skin of color represent an encouraging step, but she stressed that sustained commitment is necessary to ensure study populations reflect real-world demographics.

Beyond research, Elbuluk pointed to changes in conference programming and educational content. Speakers are becoming more intentional about including diverse imagery in lectures, and sessions addressing conditions that disproportionately affect patients of color are more visible. Importantly, she noted that skin of color dermatology is increasingly integrated throughout meetings and curricula, rather than siloed as a standalone topic, an evolution that reinforces its relevance to all clinicians.

Collectively, the panelists conveyed cautious optimism. Meaningful gains have been made in therapeutics, education, and representation, but structural and clinical gaps remain. For dermatologists in practice, the message was clear: progress matters only if accompanied by honest appraisal and continued action to ensure equitable, evidence-based care for all patients.

Editor’s note: This summary was developed with the help of AI tools.

Videos

In this segment from the latest episode of the Skin of Color Savvy podcast, progress in skin health equity and advancements still needed in 2026 are highlighted.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a comprehensive update on the rapidly evolving landscape of incretin-based therapies, focusing on newly published and top-line clinical trial data across oral GLP-1 receptor agonists and emerging triple agonists.

00:00:22 Orforglipron in the ACHIEVE-3 trial

00:10:28 Retatrutide in the TRIUMPH-4 trial

00:18:26 Topline data on Novo Nordisk's UBT251

00:21:47 Price cuts on Ozempic, Rybelsus, and Wegovy in 2027

The discussion begins with the phase 3 ACHIEVE-3 trial evaluating orforglipron, a novel, nonpeptide, once-daily oral GLP-1 receptor agonist, studied head-to-head against oral semaglutide in 1,698 adults with type 2 diabetes inadequately controlled on metformin. Orforglipron demonstrated superior glycemic efficacy, achieving mean A1C reductions of 1.7% and 1.9% at the 12 mg and 36 mg doses, respectively, compared with 1.2% and 1.5% reductions seen with 7 mg and 14 mg oral semaglutide. All primary noninferiority endpoints were met, with statistical superiority observed across comparisons. Weight reduction also favored orforglipron.

However, the enhanced efficacy was accompanied by higher rates of gastrointestinal adverse events. Nausea and other GI symptoms were reported in approximately 58–59% of patients receiving orforglipron versus 37–45% with semaglutide. Importantly, treatment discontinuation due to GI events remained relatively low (6% with orforglipron vs 3% with semaglutide), suggesting tolerability may be manageable in clinical practice. The hosts emphasize the importance of understanding how adverse events are captured in trials and highlight the role of dose titration, dietary counseling, and supportive medications in mitigating side effects. A key limitation noted is the absence of cardiovascular outcomes data for orforglipron, particularly given established cardiovascular benefit with oral semaglutide, underscoring the need for outcomes-driven decision-making in high-risk populations.

Attention then shifts to top-line results from the phase 3 TRIUMPH-4 trial evaluating retatrutide, a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, in individuals with obesity and osteoarthritis. Over 68 weeks, retatrutide achieved mean weight reductions of 26.4% to 28.7% (up to 71.2 pounds), representing some of the most substantial weight loss observed in pharmacotherapy trials to date. Nearly half of participants achieved ≥25% weight loss, and up to 23.7% achieved ≥35% reduction. Clinically meaningful improvements in osteoarthritis symptoms were documented via WOMAC scoring, with one in eight participants reporting complete resolution of knee pain. Gastrointestinal adverse events were dose-dependent, and discontinuation rates ranged from 12% to 18%, reinforcing the importance of balancing efficacy with tolerability.

The hosts also review early phase 2 data from Novo Nordisk’s investigational triple agonist (UBT251), which demonstrated 19.7% weight loss over 24 weeks in a Chinese cohort, along with improvements in waist circumference, glycemia, blood pressure, and lipids. Although preliminary, these findings highlight growing competition in the triple-agonist space and suggest continued acceleration in therapeutic innovation.

The episode concludes with broader reflections on expanding indications for incretin-based agents, including cardiovascular disease, osteoarthritis, sleep apnea, and potentially other cardiometabolic and inflammatory conditions, alongside discussion of anticipated price reductions and increased market competition. Isaacs and Bellini characterize the current era as transformative, with incretin-based therapies poised to substantially reshape cardiometabolic risk reduction strategies in type 2 diabetes and obesity.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. February 26, 2026. Accessed March 2, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. Accessed March 2, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

Novo Nordisk. Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China. 

. February 24, 2026. Accessed March 2, 2026. 

https://www.globenewswire.com/news-release/2026/02/24/3243205/0/en/Novo-Nordisk-Triple-agonist-UBT251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-China.html

Podcasts

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Obstructive hypertrophic cardiomyopathy(oHCM)is increasingly recognized earlier in the disease course, and treatment goals have evolved beyond simple symptom relief toward optimization of left ventricular outflow tract (LVOT) gradient, functional capacity, and preservation of systolic function.


In this context, Matthew Martinez, MD, highlights how cardiac myosin inhibitors have reshaped long-term management, shifting clinicians away from waiting for New York Heart Association class III or IV symptoms before intervening. Instead, the focus is now on achieving minimal or absent obstruction and enabling patients to maintain a high quality of life with minimal activity limitations.

Mariko Harper, MD, describes a marked increase in early referrals and the use of cardiac myosin inhibitors as once-daily oral therapies that can be introduced before patients develop debilitating symptoms. Both experts stress that many patients labeled “asymptomatic” in chart documentation demonstrate functional limitations when formally assessed, particularly younger patients who may normalize chronic exertional intolerance. To better delineate symptoms, they routinely employ stress echocardiography and cardiopulmonary exercise testing, which frequently reveal objective impairment despite a subjective report of minimal or no symptoms.

In this discussion, Martinez and Harper underscore long-term care in oHCM now demands proactive identification of patients with latent functional compromise and hemodynamically significant gradients. The conversation frames cardiac myosin inhibitors as central agents in modern management, integrated with advanced physiologic testing to more accurately classify symptom status and tailor treatment intensity over time. This segment serves as a foundational overview of how expert centers are redefining “asymptomatic” disease and reorienting management toward earlier and more precise intervention.

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.

Video Series

Wei-Xing Zong, PhD, is Distinguished Professor and Chair of the Department of Chemical Biology at Rutgers University.

Liver cancer, most commonly hepatocellular carcinoma (HCC), remains one of the deadliest malignancies worldwide, frequently developing in the setting of chronic liver disease. As the liver’s central role in metabolism becomes increasingly recognized in cancer biology, researchers have sought to better understand how disruptions in nutrient processing and waste detoxification may contribute to tumor development and progression.

, investigators from Rutgers University identified a metabolic vulnerability linked to impaired ammonia detoxification. When the liver’s urea cycle enzymes are downregulated, ammonia generated from dietary protein is not efficiently cleared. Rather than remaining a passive toxin, excess ammonia can be recycled into amino acids and nucleotides that fuel tumor growth, effectively turning metabolic waste into a resource for cancer cells.

Using preclinical models, the team demonstrated that impaired ammonia clearance accelerated tumor burden and reduced survival. Of note, lowering dietary protein reduced ammonia levels, slowed tumor growth, and improved outcomes in these models, suggesting that nitrogen load may directly influence liver cancer progression.

For additional insight into his team’s research and the clinical significance of their findings, the editorial team of 

 spoke with Wei-Xing Zong, PhD, Distinguished Professor and Chair of the Department of Chemical Biology at Rutgers University, in the following Q&A:

: What clinical questions or uncertainties about ammonia were you seeking to address in your research?

Zong: For a long time, clinicians have observed that patients with liver cancer often suffer from hyperammonemia, so high ammonia levels in their body. Traditionally, this has been viewed as a symptom of liver failure, as a consequence of patients getting liver cancer, instead of considering whether this may be a causal factor for liver cancer. It’s also been observed that in liver cancer patients, the ammonia detoxification enzymes, which are called urea cycle enzymes, they're often turned off. So, why is that? Whether that plays a role in liver cancer development that's also not known. And then finally, whether there are ways of intervening this, you know, is also unclear, so that was the question that we're trying to target or address.

: What are some of the key findings you report?

Zong: We were trying to address the question three fold. One was to determine whether the increased ammonia level is a cause for liver cancer. And also, if the answer is yes, what does ammonia do? What role does ammonia play in the cancer development process? And finally, whether there are ways to clinically target this problem. So to address this, we have used a system that we can manipulate the urea cycle enzymes, the ammonia detoxification enzymes in the healthy liver. We saw that by down regulating or by inhibiting these enzymes, the animals we did this in, the mouse models of liver cancer, the animals develop liver cancer much faster. Then we decided, where does the ammonia go? By getting rid of this cycle, the ammonia detoxification enzymes, ammonia accumulates in the animals, and then we determine where does ammonia go, right in terms of the biochemical pathways. So we found ammonia now gets shown to the synthesis of certain proteins and also the nucleic acid, because nucleic acids like DNA, RNA, contain nitrogen, so that's where the ammonia can contribute to that will help tumor cell growth. And then lastly, we also try it the other way. So if we find increased ammonia is really helping the tumor cells to grow, and then, whether by reducing or minimizing the ammonia level, whether we can kind of suppress the tumor growth, which we tried by lowering the dietary protein level, we did see a quite striking benefit of reducing liver cancer development.

: Do you see a role for ammonia levels or urea cycle dysfunction as biomarkers for HCC risk or progression?

Zong: From our study, we would think the ammonia levels and also urea cycle dysfunction, the decreased expression of those enzymes, look like promising biomarkers for HCC risk assessment, especially in the patients with chronic liver disease, because often they also have dysfunctional ammonia detoxification enzymes. So we would say the biological rationale is pretty strong there, and higher ammonia levels definitely are associated with worse liver function, more aggressive tumor biology, at least in our preclinical models. However, with that, we also should be a little careful with this. Although this concept is very attractive, there could also be issues such as specificity issues, because many other liver conditions other than liver cancer may also cause this increased ammonia level. There are also certain medical conditions like infection, sarcopenia, like muscle waste, or certain medications. For example, even the medications for treating certain diseases can also cause the disturbance of the ammonia level. In that sense, we cannot solely rely on just ammonia level. We think it's better to use it together to stratify with other markers as a combination.

: How do we reconcile current standard practices on protein intake from clinical guidelines with these new mechanistic findings?

Zong: The recommendation for many types of patients, including liver disease patients, is to use high protein to maintain the muscle mass and to maintain a strong enough immune system. So how can we reconcile this if we suggest that by lowering dietary protein, you can reduce the risk of liver cancer? We've been thinking about this, and there are several thoughts that we have. So one important thought is that the timing of intervention actually could be very important. For lowering the cancer risk, maybe it's important to specifically recommend this in the patients who already show the signs of early stage of liver cancer, or the patients who already are carrying the oncogenic mutations that can be detected. We think that in this more specific group of patients, lowering the dietary dietary protein could be a good, effective strategy. Another important idea I think many people are actually using now is not just to look at the quantity of the protein, but also the quality of protein could be very important. For example, the protein from plant or dairy resources could be healthier than protein from red meat, so that's another consideration. There are also certain amino acids in the protein, for example, the branched chain amino acids, that are considered low ammonia producing amino acids, so they may be healthier than the high ammonia producing amino acids. We think by looking at this by target, by targeting a specific group of patients, and by considering these different sources of proteins or different types of amino acids, this can help reconcile the idea of the trade off of getting sarcopenia or reducing cancer risk.

: Beyond diet, what therapeutic opportunities does this study point to, and which seem most realistic for clinical translation?

Zong: There are several methods that we can consider in addition to lowering dietary protein. One is to use the chemical or pharmacological scavengers of ammonia. These are the chemicals that combine to form ammonia and then convert them into the non-toxic form of nitrogen, therefore, now they don't get to be used by the tumor cells. Another way is, as we know that most of the ammonia in our body is produced in the gut by gut microbiome and certain bacteria in the gut, certain antibiotics can be used just to wipe out the gut microbiome, and then that can help reducing the ammonia production in our body. Then, thinking about the whole molecular pathways, we were talking about how ammonia can be imported into cancer cells, or ammonia in the cancer cells can be converted into other forms of metabolites, for example, other amino acids or nucleotides. Then we can think of ways of incubating these other ammonia importers, or the enzymes that convert ammonia to these metabolites that are used by the tumor cells. By incubating these enzymes, we can also try to intervene with this whole ammonia pathway. Finally, by suppressing the enzymes that can convert ammonia into nucleotides, or by converting by activating the growth signaling, such as mTOR signaling or a KT pathway, these can also help reduce the effect of ammonia in promoting tumor growth.

Editors’ Note: Zong reports no relevant disclosures.

Han X, Shen J, Yan J, et al. Impaired nitrogenous waste clearance promotes hepatocellular carcinoma. 

. 2026;12(2):eaec0766. doi:10.1126/sciadv.aec0766

Rutgers. How a Simple Dietary Change May Slow Liver Cancer in At-Risk Patients. January 9, 2026. Accessed March 2, 2026. 

https://www.rutgers.edu/news/how-simple-dietary-change-may-slow-liver-cancer-risk-patients

Articles

Hepatocellular carcinoma may exploit hyperammonemia as a growth substrate when urea cycle enzymes are downregulated, shifting ammonia from detoxification toward anabolic nitrogen recycling. In preclinical liver cancer models, impaired ammonia clearance increased tumor burden and shortened survival, while dietary protein reduction lowered ammonia and slowed tumor progression. Ammonia and urea cycle dysfunction emerge as candidate risk/progression biomarkers, albeit limited by confounding etiologies. Translational concepts include ammonia scavengers, microbiome modulation, and inhibiting ammonia transport and nitrogen-assimilation pathways.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management. 

Hepatology

Dietary Protein as a Modifiable Risk Factor in Liver Cancer, With Wei-Xing Zong, PhD

Berotralstat Cuts HAE Attack Burden in APeX-P Interim Analysis, With Jolanta Bernatoniene, MD, PhD

experienced sustained reductions in moderate and severe attacks over 48 weeks of oral berotralstat therapy, according to interim data from the phase 3 APeX-P study presented at the 

2026 American Academy of Allergy, Asthma & Immunology (AAAAI)

In an interview at the meeting, Jolanta Bernatoniene, MD, PhD, from Bristol Royal Hospital for Children, discussed the clinical implications of the findings and how an oral long-term prophylaxis option may shift pediatric HAE management.

“It was [a] significant reduction,” Bernatoniene said. “For example, at the baseline, the median attack rate [was] almost 0.96. We've seen very early and sustained reduction to almost 0.”

APeX-P is an ongoing, open-label study evaluating the pharmacokinetics, safety, and efficacy of berotralstat, an oral plasma kallikrein inhibitor, in children with HAE. Participants remained on standard of care for 12 weeks before initiating berotralstat, allowing for within-patient comparisons.

The study enrolled 29 children aged 3 to 11 years. During the standard-of-care period, patients reported a median of 0.96 total monthly attacks, including 0.33 moderate and 0.31 severe attacks per month. After initiating berotralstat, reductions were observed as early as the first month of treatment. Over 48 weeks, the median monthly rate of moderate attacks decreased to 0.16, while severe attacks declined to 0.0.

Beyond attack frequency, the overall symptom burden also improved. During standard of care, patients experienced HAE symptoms on a median of 9% of days (range, 0%–40%). Over 48 weeks of berotralstat treatment, this fell to a median of 3% of days (range, 0%–10%).

Pediatric onset was common and early. Bernatoniene said that the median age of disease onset in the study population was approximately 2 years, and most children presented with symptoms before 6 years old. These findings underscore the need for effective long-term prophylaxis options in younger patients, who may experience substantial disease burden during critical developmental years.

The safety profile was favorable. Adverse events were consistent with prior berotralstat studies, and no grades 3 or 4 drug-related adverse events were reported. No patients discontinued therapy because of adverse events.

The approval of berotralstat by the US Food and Drug Administration (FDA) in December for this age group marks the first oral long-term prophylaxis option for children under 12 years of age with HAE.

 Previously available prophylactic therapies required subcutaneous or intravenous administration, which can impose a significant burden on patients and families. Berotralstat is administered as small oral pellets that can be sprinkled and are easy for caregivers to deliver.

“Patients are happy, parents are happy, clinicians are happy [with berotralstat],” Bernatoniene said. “In practice, the drug is very well accepted already by the families, by the clinicians. It’s already approved by [the] FDA. It’s [going to] … probably [be] first line recommended treatment for [HAE] for the children less than 12.”

Bernatoniene J, Bourgoin-Heck M, Cancian M, et al. Oral Berotralstat Reduces the Rate of Moderate and Severe Attacks and Percentage of Days with HAE Symptoms Over 48 Weeks in Children Aged 2 to Less Than 12 Years: Interim Data from APeX-P. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2025.12.120

Derman C. FDA Approves Oral Berotralstat for Children Aged 2 – 11 Years with HAE. HCPLive. January 5, 2026. Accessed on March 2, 2026. 

https://www.hcplive.com/view/fda-approves-oral-berotralstat-children-aged-2-11-years-hae

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up with FDA decisions, key trial results, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Arrhythmia

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Dyslipidemia

5 Cardiology Headlines You Missed in February 2026

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

ADVANCE OUTCOMES: Ralinepag Outperforms Placebo in Slowing Disease Progression in PAH

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

AFFIRM: Risankizumab (Skyrizi) Subcutaneous Induction Achieves Primary Endpoints in Crohn’s Disease

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera. 


Hematology

FDA News

FDA Accepts New Drug Application for Rusfertide, Grants Priority Review In Polycythemia Vera

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.

Future Advancements in PBC Care: Innovations on the Horizon

Neal Bhatia, MD, speaks on new data on ixekizumab and tirzepatide for weight loss and psoriasis, as well as the implications of these data regarding GLP-1 use.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing GLP-1 or Dual Incretin Therapies in IL-17 Mediated Disease, With Neal Bhatia, MD

Medical student at John Sealy School of Medicine, University of Texas in Galveston

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Addressing ICS Hesitancy in Pediatric Asthma Care, With Lynchi Nguyen

Jose Clemente, PhD, associate professor of Genetics and Genomics and Immunology at the Icahn School of Medicine at Mount Sinai

Early gut microbiome changes in c-section infants linked to food sensitization at 12 months, highlighting a potential critical intervention window.

Food Allergy

Early Microbiome Shifts May Define a Critical Window for Allergy Risk, With Jose Clemente, PhD

Trial data show early microbiome shifts after vaginal microbial transfer in cesarean-delivered infants, with differences in food sensitization at 12 months.

Vaginal Seeding Partially Modifies Infant Microbiome in ACTIVATE, With Jose Clemente, PhD

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.

Latest News

Where Are We in 2026 in Skin Health Equity Progress?

Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

Dietary Protein as a Modifiable Risk Factor in Liver Cancer, With Wei-Xing Zong, PhD

Berotralstat Cuts HAE Attack Burden in APeX-P Interim Analysis, With Jolanta Bernatoniene, MD, PhD